Journal Title：Anti-cancer Drugs

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.

《抗癌藥物》報道與抗癌藥物相關的臨床和實驗結果，并歡迎有關抗癌藥物設計、藥物輸送、藥理學、激素和生物學方式以及化療評估的投稿。《抗癌藥物》是一份國際公認的期刊，致力于快速發(fā)表抗癌治療劑的創(chuàng)新研究，旨在促進和報道有毒和無毒抗癌劑的研究。因此，該期刊的范圍將涵蓋傳統(tǒng)的細胞毒性化療和激素或生物反應方式，如白細胞介素和免疫療法。提交的文章將由編輯進行初步審查。有些文章可能會退還給作者，無需進一步考慮。那些正在考慮發(fā)表的文章將由編輯和受邀的審稿人進行進一步評估和同行評審。

Anti-cancer Drugs創(chuàng)刊于1990年，由Lippincott Williams and Wilkins Ltd.出版商出版，收稿方向涵蓋醫(yī)學 - 藥學全領域，此期刊水平偏中等偏靠后，在所屬細分領域中專業(yè)影響力一般，過審相對較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機率較高。平均審稿速度 偏慢,4-8周 ，影響因子指數(shù)1.8，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。